Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy

European Respiratory Review

Volumn 24, Issue 135, 2015, Pages 46-51

  Teschler, Helmut ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN CONCENTRATE; PLACEBO; ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; AUGMENTATION THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE COURSE; DISEASE EXACERBATION; DRUG RESPONSE; EMPHYSEMA; ENZYME REPLACEMENT; GERMANY; GRAFT RECIPIENT; HUMAN; LUNG INFECTION; PANNICULITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ULCERATIVE COLITIS; WEGENER GRANULOMATOSIS; ALPHA 1-ANTITRYPSIN DEFICIENCY; LUNG TRANSPLANTATION; PULMONARY EMPHYSEMA;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; DISEASE PROGRESSION; HUMANS; LUNG TRANSPLANTATION; PULMONARY EMPHYSEMA; QUALITY OF LIFE;

EID: 84923862550     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.10010714     Document Type: Article

References (22)

1. Mohanka M, Khemasuwan D, Stoller JK. A review of augmentation therapy for alpha-1antitrypsin deficiency. Expert Opin Biol Ther 2012; 12: 685–700.
2. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055–1062.
3. 1-antitrypsin in the general population. Thorax 2012; 67: 669–674.
4. Barker AF, Iwata-Morgan I, Oveson L, et al. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997; 112: 607–613.
5. Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988; 260: 1259–1264.
6. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 2225–2236.
7. Stoller JK, Aboussouan LS. Alpha1-Antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59: 708–712.
8. 1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158: 49–59.
9. 1-antitrypsin deficiency? Eur Respir J 1997; 10: 2260–2263.
10. Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1antitrypsin deficiency: a meta-analysis. COPD 2009; 6: 177–184.
11. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818–900.
12. 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468–1472.
13. 1-antitrypsin deficiency. Eur Respir J 2009; 33: 1345–1353.
14. Stockley RA, Parr DG, Piitulainen E, et al. Therapeutic efficacy of α-1antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 136.
15. Chapman KR, Burdon JGW, Piitulainen E, et al. IV alpha1antitrypsin (a1aT) preserves lung density in homozygous alpha1antitrypsin deficiency (a1atd): a randomized, placebo-controlled trial. Am J Respir Crit Care Med 2013; 187, A6069.
16. 1-protease inhibitor. Chest 2001; 119: 737–744.
17. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480–1485.
18. Barros-Tizón JC, Torres ML, Blanco I, et al. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis 2012; 6: 67–78.
19. Köhnlein T, Janciauskiene S, Welte T. Diagnostic delay and clinical modifiers in alpha-1antitrypsin deficiency. Ther Adv Respir Dis 2010; 4: 279–287.
20. Wilke A, Grohé C. Prospektive Untersuchung klinischer Verlaufsparameter von Patienten mit Alpha-1-Antitrypsinmangelsyndrom unter i.v. Prolastin-Heimtherapie [Prospective evaluation of clinical parameters of AAT patients with i.v. prolastin therapy in a homecare setting]. Pneumologie 2013; 67: 545–550.
21. Stockley RA, Turner AM. α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol Med 2014; 20: 105–115.
22. 1-antitrypsin deficiency. Am J Respir Crit Care Med 2014; 190: 274–281.